Thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
It is home to the headquarters of three Fortune Global 500 companies, the highest in the region. The nation's best known global companies include Singapore Airlines, Changi Airport, and the Port of Singapore, all of which are among the most-awarded in their respective fields. Singapore Airlines was ranked as Asia's most-admired company, and the world's 19th most-admired company in 2015 by Fortune's annual "50 most admired companies in the world" industry surveys. Other awards it has received include the US-based Travel + Leisure's Best International Airline award, which it has won for 20 consecutive years. Changi Airport connects over 100 airlines to more than 300 cities. The strategic international air hub has more than 480 World's Best Airport awards as of 2015, and is known as the most-awarded airport in the world. Over ten free-trade agreements have been signed with other countries and regions. Singapore is the second-largest foreign investor in India. It is the 14th largest exporter and the 15th largest importer in the world.
== Pharmacokinetics == With the once-monthly formulation of paliperidone palmitate, the time to peak is 13 days and the elimination half-life is 25 to 49 days; for the 3-month formulation, the time to peak is 30 to 33 days and the half-life is 84 to 95 days (deltoid muscle) or 118 to 139 days (gluteal). These data come from a 2021 review whose authors included employees of Janssen Research & Development, the manufacturer of paliperidone palmitate. The peak-to-trough ratio of paliperidone palmitate at steady state ranges from 1.56 to 1.70 with the 1- and 3-month formulations. No pharmacokinetic data for the 6-month formulation has been released as of January 2021. However, a 2025 case report described a patient who still had measurable plasma paliperidone concentrations in the low therapeutic range 886 days (2.5 years) after her last injection, indicating that in some individuals the drug may be released from the depot far longer than the predicted half‑life. The pharmacokinetic profile was originally derived from a 2009 pooled analysis of 18,530 paliperidone concentration samples from 1,795 subjects across six Phase I trials and five Phase II and III trials funded by Johnson & Johnson Pharmaceutical Research and Development, LLC. Invega Sustenna, Invega Trinza, and Invega Hafyera all utilize nanoparticle technology. The NanoCrystal® technology used in all three long-acting paliperidone products is manufactured by Alkermes plc.
=== Cancer === Current clinical trials testing synthetic platelets offer a promising strategy for oncology applications by facilitating targeted drug delivery to tumors and reducing off-target toxicity in cancer therapy. Natural platelets were reported to interact with cancer cells through mechanisms such as immune evasion, angiogenesis, and metastasis. Specific to oncology, synthetic platelets are applied using targeted drug delivery. Platelet-mimicking nanoparticles developed from self-assembling peptides were found to adhere to tumor endothelial cells and induce localized coagulation, forming artificial clots that disrupt tumor vasculature. This approach reduces blood supply to the tumor, effectively starving cancer cells while preventing metastatic spread. Furthermore, synthetic platelets designed to deliver chemotherapy drugs can leverage natural platelet-tumor interactions to deliver drugs directly to cancerous cells, which has been seen to reduce off-target effects and improve therapeutic outcomes. Immunotherapy and radiation sensitization are additional application areas of platelet-mimicking particles. Platelet-inspired nanomedicine uses extracellular vesicles and platelet-derived biomaterials to enhance immune responses against tumors. These biomimetic platforms can be designed to carry immune checkpoint inhibitors and pro-inflammatory cytokines, which can help overcome immune evasion mechanisms employed by cancer cells.
Sources: en.wikipedia.org
The Mazda Familia (Japanese: マツダ ファミリア, Matsuda Famiria), also marketed prominently as the Mazda 323, Mazda Protegé and Mazda Allegro, is a small family car that was manufactured by Mazda between 1963 and 2003. The Familia line was replaced by the Mazda3/Axela for 2004. It was marketed as the Familia in Japan, which means "family" in Latin. For export, earlier models were sold with nameplates including: "800", "1000", "1200", and "1300". In North America, the 1200 was replaced by the Mazda GLC, with newer models becoming "323" and "Protegé". In Europe, all Familias sold after 1977 were called "323". The Familia was also rebranded as the Ford Laser and Ford Meteor in Asia, Oceania, Southern Africa, some Latin American countries and, from 1991, as the Ford Escort and Mercury Tracer in North America. In addition, the Familia name was used as the Mazda Familia Wagon/Van, a badge-engineered version of the Nissan AD wagon (1994–2017) and Toyota Probox (2018–present). Mazda Familias were manufactured in the Hiroshima Plant and also assembled from "knock-down kits" in various countries including Taiwan, Indonesia, Malaysia, South Africa, Zimbabwe, Colombia, and New Zealand. Some of these plants kept manufacturing the Familia long after it was discontinued at home.
=== Ba–Bee === David Baker (b. 1962). American biochemist and computational biologist at the University of Washington, who studies methods to predict and design the three-dimensional structures of proteins. Nobel Prize in chemistry, 2024. Tania A. Baker (PhD 1988). American biochemist at MIT, who has studied transposons and enzymes that catalyse protein unfolding. Member Natl. Acad. Sci. USA. Clinton Ballou (1923–2021). American biochemist at UC Berkeley, whose research focused on the metabolism of carbohydrates and the structures of microbial cell walls. Member Natl. Acad. Sci. USA. Horace Barker (1907–2000). American biochemist and microbiologist at UC Berkeley. Member Natl. Acad. Sci. USA. David Bartel (PhD 1993). American biochemist at MIT, known for work on microRNA biology. Member Natl. Acad. Sci. USA. Bonnie Bassler (b. 1962). American molecular biologist at Princeton, known for studies of quorum sensing, and the idea that disruption of chemical signalling can be used as an antimicrobial therapy. Member Natl. Acad. Sci. USA. Philip A. Beachy (b. 1958). American biochemist at Stanford, known for studies to understand the molecular mechanisms behind the growth of multicellular embryos, especially the role of the Hedgehog signalling pathway. Member Natl. Acad. Sci. USA. Jon Beckwith (b. 1935). American microbiologist and geneticist at Harvard who made important contributions to the study of bacterial genetics. Member Natl. Acad. Sci. USA.
In January 2016, Kardashian hosted the Kocktails with Khloé pop culture–themed variety talk show, which aired on the FYI cable channel. The show was cancelled after 14 episodes. Kardashian and business woman Emma Grede launched their clothing line Good American in the same year, and made $1 million in sales on the first day. Good American started by selling jeans ranging from size 00 to 24 and has expanded to a variety of clothes including workout clothes, dresses and a maternity collection. Kardashian starred and produced Revenge Body with Khloé Kardashian, an American reality television series that premiered on the E! cable network, on January 12, 2017.
In November 2007, Merck agreed to pay $4.85 billion to settle most of the pending Vioxx lawsuits. The settlement required that claimants provide medical and pharmacy records confirming the occurrence of a heart attack, ischemic stroke, or sudden cardiac death; the receipt of at least 30 Vioxx pills within 60 days prior to the injury or death; and confirmation of Vioxx being used within 14 days of the Vioxx-related event. The settlement was generally viewed by industry analysts and investors as a victory for Merck, considering that original estimates of Merck's liability reached between $10 billion and $25 billion. As of mid-2008, when the plaintiff class had reached the threshold percentage required by Merck to go through with the settlement, plaintiffs had prevailed in only three of the twenty cases that had reached juries, all with relatively small awards. Merck has refused to consider compensation for Vioxx victims and their families outside the US. This is particularly true in the UK where there are at least 400 victims and the legal protection afforded to the victims and their families is particularly weak. According to internal e-mail traffic released at a later lawsuit, Merck had a list of doctors critical of Vioxx to be "neutralized" or "discredited". "We may need to seek them out and destroy them where they live," wrote an employee. A Stanford Medical School professor said that Merck was engaged in intimidation of researchers and infringement upon academic freedom.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.